Acumen Pharmaceuticals, Inc.
corporate_fare Company Profile
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ABOS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 11 rated 8 or above. Recent SEC coverage for ABOS spans 8-K, S-3, 10-Q, DEF 14A.
Recent high-impact activity:
- Acumen Cuts 90% of Staff and Repays $23.3M Loan After Sabirnetug Failure
- Lead Alzheimer's Drug Fails Phase 2 Trial; Company Halts Development and Explores Strategic Options
- Acumen Files $500M Shelf With Cash Running to Early 2027 and Going-Concern Doubt
- Acumen Sets November 2026 ALTITUDE-AD Readout With $78.6M Cash Into Early 2027
- Q3 Loss Narrower Than Expected at $25.8M Operating, $0.35 EPS
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 4,556,267 shares in ABOS as of the October 30, 2026 settlement, a 47.4% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 19, 2026, 63.1% of ABOS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ABOS, detected from its recent SEC filings · based on capital-structure filings through 2026-10-26.
Shelf Registers Up to $500 Million · Cash Runs Out in Early 2027
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →